MUNICH--(BUSINESS WIRE)--Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced that the company will be a participant in a panel discussing big data operations and R&D efficiencies at the BIO International Convention on Thursday, June 9th.
Merrilyn Datta, chief commercial officer, Definiens, will be a featured speaker on the panel, entitled “Using Big Data for Personalizing Medicine: Insights from Genomic Data and Real World Evidence.”
“Big data will be essential to unlocking precision medicine,” said Datta. “By combining tissue data, genomics, and clinical outcomes, we will be able to better match therapies with patients. I look forward to engaging with the other participants at BIO in order to help move this important conversation forward.”
BIO 2016 will be held in San Francisco from June 6-9th, 2016. The panel will take place on June 9th in room West 3006 from 10:30-11:45am. For more information about the panel, visit www.mybio.org. For more information about Definiens’ technology, visit www.definiens.com.
Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development and commercialization. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com